Partial nephrectomy is now more frequently used in the U.S. than radical nephrectomy. A study of the U.S. Surveillance, Epidemiology and End Results (SEER) registry 2001-2009 data shows that surgery continues to be the most common treatment, with [...]
Patients with renal cell carcinoma (RCC) are at lower risk of end-stage renal disease (ESRD) requiring renal replacement therapy (dialysis or transplant) if they undergo partial rather than radical nephrectomy, a new study suggests.
The IKCC is working with the European Association of Urology (EAU) on Guidelines for kidney cancer. Several countries already have such guidelines. If there is an opportunity to create clinical guidelines in your own country, it would be worthwhile to build upon the work done in other countries.
Overall message from ASCO 2015 is that the field of cancer treatment is changing rapidly. Words such as “practice-changing” and “breakthrough” were heard often, but there is also room from some caution while we await more information from upcoming trials.
Researchers in Singapore have developed the first genomic test kit that can predict treatment and survival outcomes in kidney cancer patients.
Afinitor approved in Australia for kidney cancer.
